Fennec Pharmaceuticals Inc. (TSX:FRX)
Canada · Delayed Price · Currency is CAD 15.04
-0.25 (-1.64%)
Sep 24, 2026, 3:56 PM EST
Fennec Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 59.22 | 44.64 | 47.54 | 21.25 | 1.54 | - | |
Revenue Growth | 77.83% | -6.09% | 123.69% | 1284.50% | 802.94% | - |
Cost of Revenue | 3.72 | 3.76 | 3.18 | 1.26 | 0.09 | - |
Gross Profit | 55.51 | 40.88 | 44.35 | 19.99 | 1.45 | - |
Selling, General & Admin | 56.41 | 46.91 | 41.48 | 32.71 | 20.51 | 12.24 |
Research & Development | 0.22 | 0.25 | 0.31 | 0.06 | 3.53 | 4.98 |
Operating Expenses | 56.63 | 47.16 | 41.79 | 32.76 | 24.04 | 17.22 |
Operating Income | -1.12 | -6.28 | 2.57 | -12.77 | -22.59 | -17.22 |
Interest Expense | -0.94 | -2.14 | -4.16 | -3.68 | -1.13 | -0.14 |
Interest & Investment Income | 1.01 | 0.79 | 1.68 | 0.44 | 0.2 | 0.05 |
Currency Exchange Gain (Loss) | -0.02 | 0.03 | -0.08 | 0.01 | -0.01 | -0.01 |
EBT Excluding Unusual Items | -1.08 | -7.61 | 0.01 | -16.01 | -23.53 | -17.32 |
Gain (Loss) on Sale of Investments | - | -0 | -0.08 | -0.04 | -0.18 | -0.03 |
Other Unusual Items | -2.02 | -2.02 | - | - | - | - |
Pretax Income | -3.1 | -9.64 | -0.07 | -16.05 | -23.71 | -17.35 |
Income Tax Expense | 0.15 | 0.11 | 0.37 | - | - | - |
Net Income | -3.25 | -9.74 | -0.44 | -16.05 | -23.71 | -17.35 |
Net Income to Common | -3.25 | -9.74 | -0.44 | -16.05 | -23.71 | -17.35 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 32 | 29 | 27 | 27 | 26 | 26 |
Shares Outstanding (Diluted) | 32 | 29 | 27 | 27 | 26 | 26 |
Shares Change | 16.68% | 4.70% | 2.71% | 1.14% | 1.03% | 9.71% |
EPS (Basic) | -0.10 | -0.34 | -0.02 | -0.60 | -0.90 | -0.67 |
EPS (Diluted) | -0.10 | -0.34 | -0.02 | -0.60 | -0.90 | -0.67 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 93.73% | 91.57% | 93.30% | 94.08% | 94.40% | - |
Operating Margin | -1.90% | -14.07% | 5.40% | -60.09% | -1471.60% | - |
Profit Margin | -5.49% | -21.82% | -0.92% | -75.50% | -1544.89% | - |
EBITDA | -1.02 | -6.18 | 3.6 | - | - | - |
EBITDA Margin | -1.73% | -13.84% | 7.57% | - | - | - |
D&A For EBITDA | 0.1 | 0.1 | 1.03 | - | - | - |
EBIT | -1.12 | -6.28 | 2.57 | -12.77 | -22.59 | -17.22 |
EBIT Margin | -1.90% | -14.07% | 5.40% | -60.09% | - | - |
Revenue as Reported | 59.22 | 44.64 | 47.54 | 21.25 | - | - |